High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era
Genes · 2026
DOI: 10.3390/genes17040370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Nardi Tetaj und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Campus Bio-Medico Hospital University, Via Alvaro del Portillo 200, 00128 Roma, Italy. Hauptthemen laut MEDLINE: Cardiomyopathies, Arrhythmias, Cardiac. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inherited cardiomyopathies represent a major cause of ventricular arrhythmias (VA) and sudden cardiac death (SCD), frequently occurring in the absence of advanced systolic dysfunction. Traditional strategies for the primary prevention of SCD have relied predominantly on left ventricular ejection fraction (LVEF), an approach that fails to capture the substantial biological and clinical heterogeneity of non-ischemic cardiomyopathies. Over the past decade, advances in cardiac genetics and cardiac magnetic resonance imaging have identified specific genotypes associated with a disproportionate arrhythmic risk, which often precedes overt ventricular remodeling. The 2023 European Society of Cardiology (ESC) Guidelines on cardiomyopathies formalize this paradigm shift by integrating etiology, myocardial substrate, and electrical phenotype into contemporary risk stratification. In this narrative review, we focus on cardiomyopathy-associated genotypes consistently linked to high arrhythmic risk—LMNA, truncating variants in FLNC, RBM20, PLN p.Arg14del, and desmosomal genes—and examine their molecular mechanisms, phenotypic trajectories, and arrhythmogenic profiles. We discuss how genotype-specific patterns of myocardial fibrosis, conduction disease, and VA inform implantable cardioverter-defibrillator (ICD) decision-making beyond LVEF-based thresholds. By synthesizing genetic, imaging, and clinical evidence in light of ESC 2023 recommendations, this review highlights the evolving role of genotype-informed strategies in the personalized prevention of SCD and underscores remaining gaps in evidence and risk prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Unit, Campus Bio-Medico Hospital University, Via Alvaro del Portillo 200, 00128 Roma, Italy.
- Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Campus Bio-Medico Hospital University, Via Alvaro del Portillo 21, 00128 Roma, Italy.
ORCID-Profile: Nardi Tetaj, Andrea Segreti
Zitieren
APA
Tetaj, N., Segreti, A., Ferro, A., Ligorio, V., Spagnolo, A., & Grigioni, F. (2026). High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era. Genes. https://doi.org/10.3390/genes17040370
Vancouver
Tetaj N, Segreti A, Ferro A, Ligorio V, Spagnolo A, Grigioni F. High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era. Genes. 2026. doi:10.3390/genes17040370
BibTeX
@article{Tetaj2026,
author = {Tetaj, Nardi and Segreti, Andrea and Ferro, Aurora and Ligorio, Virginia and Spagnolo, Alberto and Grigioni, Francesco},
title = {High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17040370}
}
EUVIMED